This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third View: Delving into the Phase 3 ALIGN clinical trial of atrasentan in patients with IgA nephropathy.
Ticker(s): NVSWho's the expert?
Institution: Texas A&M University
- Clinical Assistant Professor of Medicine at Texas A & M University.
- Partner at Dallas Nephrology Associates, Owner at Vel Consulting
- Staff Physician at the Baylor Regional Transplant Institute.
- On average sees around 75 patients a week and is involved in the full spectrum of kidney disease care including chronic kidney disease, end stage renal disease, transplantation, and dialysis.
Interview Goalto discuss the current standard of care and the potential of atrasentan, a therapy being developed by Novartis for the treatment of IgAN.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
